Nissen, who has said for some time that new drugs to treat high cholesterol are needed, is now on the side of a drug developer. He’s endorsing a clinical trial for eprotirome that could cut its length and cost in half, according to Bloomber...
A new Alzheimer’s disease test developed by a Durham, North Carolina, pharmaceutical company has been licensed by Takeda Pharmaceutical Co. in a deal valued at up to $87 million.
Under the agreement announced this week, Zinfandel Pharmaceut...
Dr. Steven Nissen, the Cleveland Clinic’s high-profile cardiovascular medicine chair, is staking his reputation as a drug-safety advocate on a shortened regulatory pathway for a cholesterol-fighting drug made by a Swedish company, according...
We use cookies to keep you signed in, remember your preferences and measure how the site is used. By continuing to browse Parsers VC you agree to that. Privacy & Terms
How would you rate Parsers VC?
On a scale from 1 to 10, how would you rate Parsers VC overall? It takes one click and helps us decide what to improve.
1 – poor10 – excellent
Thank you!
Your rating helps us make Parsers VC better.
Your rating was not saved
Something went wrong on our side. We will ask you again on one of your next visits.
Enjoying Parsers VC?
Thank you for rating Parsers VC so highly. Would you share your experience on G2? A short review helps other investors and founders find us.